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Abstract
Polyclonal Epstein-Barr virus (EBV)-infected B cell line (lymphoblastoid cell lines; LCL)-stimulated T-cell preparations have
been successfully used to treat EBV-positive post-transplant lymphoproliferative disorders (PTLD) in transplant recipients,
but function and specificity of the CD4+ component are still poorly defined. Here, we assessed the tumor-protective
potential of different CD4+ T-cell specificities in a PTLD-SCID mouse model. Injection of different virus-specific CD4+ T-cell
clones showed that single specificities were capable of prolonging mouse survival and that the degree of tumor protection
directly correlated with recognition of target cells in vitro. Surprisingly, some CD4+ T-cell clones promoted tumor
development, suggesting that besides antigen recognition, still elusive functional differences exist among virus-specific T
cells. Of several EBV-specific CD4+ T-cell clones tested, those directed against virion antigens proved most tumor-protective.
However, enriching these specificities in LCL-stimulated preparations conferred no additional survival benefit. Instead, CD4+
T cells specific for unknown, probably self-antigens were identified as principal antitumoral effectors in LCL-stimulated T-cell
lines. These results indicate that virion and still unidentified cellular antigens are crucial targets of the CD4+ T-cell response
in this preclinical PTLD-model and that enriching the corresponding T-cell specificities in therapeutic preparations may
enhance their clinical efficacy. Moreover, the expression in several EBV-negative B-cell lymphoma cell lines implies that
these putative autoantigen(s) might also qualify as targets for T-cell-based immunotherapy of virus-negative B cell
malignancies.
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About 20% of all human cancers are caused by pathogens
and of these 80% by viruses [1]. The viral proteins expressed in
these tumors represent neo-antigens and potential targets for
immunotherapeutic approaches [2]. The oncogenic Epstein-
Barr virus (EBV), a member of the gamma-herpes virus family,
has been implicated in the pathogenesis of several human
malignancies of lymphoid and epithelial origin [3]. Acquired
orally, EBV persists lifelong in the human host by establishing
latency in B cells but is normally contained as an asymptomatic
infection by T-cell surveillance. Consequently, patients with T-
cell immunodeficiency are at heightened risk of developing
EBV-associated malignancies [3]. In immunosuppressed hema-
topoietic stem cell transplant (HSCT) recipients, such EBV-
positive post-transplant lymphoproliferative disorders have been
successfully treated by the infusion of polyclonal EBV-specific
T-cell preparations that are generated by repeated stimulation
of peripheral blood T cells with autologous EBV-infected B cells
(LCL) in vitro and contain CD8+ and CD4+ T-cell components
[4–6].
Despite its proven safety and remarkable efficacy, adoptive T-
cell therapy still has a limited role in the management of virus-
associated complications in transplant recipients, mainly because
of the logistical and financial implications that are associated with
extensive in vitro T-cell culture, as well as the time required to
generate virus-specific T-cell lines when the clinical need is urgent.
To expedite the preparation procedure, various protocols have
been designed that aim at isolating effector populations directly
from stem cell donors, including ex vivo selection of defined EBV
antigen-specific T cells with pentamers [7], or cytokine secretion
and capture technology [8,9]. Moreover, the recently established
repository of cryopreserved virus-specific T-cell lines from healthy
seropositive donors provides partially HLA-matched, off-the-shelf
products for adoptive transfer [10]. Given the difficulty of
generating virus-specific T-cell lines from EBV-naive donors in
vitro, recipients of stem cells from cord blood might particularly
benefit from such allogeneic effectors [3,5,6]. Of note, the success
of immunotherapy seen in HSCT recipients has not been matched
in solid organ transplant (SOT) patients, most likely because the
continuous immunosuppressive environment limits proliferation
and persistence of adoptively transferred cells. Response rates in
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SOT recipients with refractory PTLD that were treated with
autologous or allogeneic LCL-stimulated T-cell preparations were
reported to range around 50% [5,6]. Importantly, better clinical
responses were observed when the infused T cells expressed a
broad T-cell receptor repertoire [11], suggestive of a broadly
targeted T-cell response, and when they contained higher
proportions of CD4+ T cells [10,11]. For unknown reasons, the
CD4/CD8 T-cell ratio in LCL-stimulated T-cell lines can vary
greatly [12,13]. These findings imply that the clinical efficacy of T-
cell preparations may be increased by tailoring its cellular
composition and, in extension, antigen specificity. However, in
contrast to the well-characterized EBV-specific cytotoxic CD8+ T-
cell response [3,14], relatively little is known about function and
specificity of virus-specific CD4+ T cells. Ex vivo analyses of latent
antigen-specific CD4+ T-cell memory has led to the identification
of multiple epitopes, and virus carriers usually exhibit memory
responses to several epitopes that are derived from more than one
antigen [15–17]. For the few lytic cycle antigens examined to date,
again multiple reactivities were detected per donor [18–20],
indicating that the EBV-specific CD4+ T-cell response is broadly
distributed across different latent and lytic cycle antigens. A similar
pattern of antigen specificity was detected in LCL-stimulated T-
cell preparations. Besides viral antigen-specific T cells, these lines
also contain CD4+ T cells specific for cellular antigens, whose
expression is probably up-regulated by EBV infection [20,21]. The
remarkable breadth of the virus-specific CD4+ T-cell response and
the fact that classical PTLD, like LCL, express all latent antigens
of EBV and contain lytically infected cells expressing ,80 lytic
cycle proteins [3,22], raises the question, whether the different
CD4+ T-cell specificities are equally tumor-protective or whether
some have non-redundant functions in tumor control and,
therefore, should be enriched in T-cell preparations for adoptive
therapy.
Here, we used the well-established PTLD-SCID mouse model
[23,24], that permits to assess efficacy of T-cell preparations in a
preclinical setting [25], to comparatively evaluate the tumor-
protective potential of different CD4+ T-cell specificities in vivo.
Results
Induction of CD20+ EBV+ PTLD-like tumors in SCID mice
by different cell types
To assess the tumor-protective potential of different T-cell
populations in the PTLD-SCID mouse model [24,26–28], mice
were i.p. injected with 16107 LCL or 56107 PBMC from EBV-
positive donors and tumor incidence, latency and localization
analyzed. After injection of LCL, PTLD-like tumors developed
with 100% incidence in three out of four cases (Figure 1A) with a
latency of 20 to 46 days. Tumors usually developed with slightly
delayed kinetics when LCL Z(-) of the same donor were injected
(Figure 1B). Tumor latency was also extended when reduced
numbers of LCL were injected (Figure 1C). Injection of PBMC
from EBV-seropositive donors also led to tumor development but
with much slower kinetics (Figure 1B). Tumors either formed
below the liver and were then often connected with the porta
hepatis, or were located at the injection site. Human origin and
PTLD-like histology of the tumors was verified by measuring
huIgG in mouse serum (data not shown) and by immunohisto-
chemical analysis of tumor sections [29]. Although PBMC-
induced tumors were more heterogeneous in their cellular
composition, all tumors expressed human CD20 and the EBV-
proteins EBNA1 and EBNA2 (Figure 1D).
The CD4+ and CD8+ component of LCL-stimulated T-cell
preparations have similar tumor-protective potential in
vivo
To compare the tumor-protective efficacy of CD4+ versus
CD8+ T cells in vivo, T-cell lines were generated from several
donors by four rounds of in vitro stimulation with autologous LCL
and then separated into CD4+ and CD8+ subsets by MACS. Mice
that had received 16107 LCL were i.p. injected on the same day
with an equal number of the separated (n = 4–7), or, as control, the
unseparated T cells (n = 6) on the opposite flank. Although T-cell
preparations from different donors proved differently effective,
mouse survival was consistently prolonged to the same extent by
the CD4+ and CD8+ components (Figure 2A), indicating that
both T-cell subsets possess similar tumor-protective capacity.
Because the single components were not as efficacious as the
parental T-cell line, and because T-cell preparations with higher
CD4+ numbers had shown better clinical responses [10], CD4+
and CD8+ T-cell subsets were recombined at different ratios
ranging from 0–100% CD4+ T cells, and tested in the same way.
None of the combinations, including reconstituted CD4/CD8
ratios of the parental T-cell lines (group size n = 4), showed
enhanced tumor protection (Figure 2B). These results suggested
that the T-cell subsets have additive but not synergistic effects on
mouse survival and that the comparatively lower tumor-protective
effect of the subset combinations might have been due to an
impaired fitness or vitality of the T cells following the separation
procedure.
Different EBV-specific CD4+ T-cell clones can have
opposing effects on mouse survival in vivo
Given the remarkable breadth of the EBV-specific CD4+ T-cell
response, we sought to investigate whether and to which extent
single CD4+ T-cell clones were able to delay tumor growth, and
whether tumor protection in vivo correlated with target cell
recognition and inhibition of proliferation in vitro [19]. To this
Author Summary
The c-herpesvirus Epstein-Barr virus (EBV) is associated
with several human malignancies, including post-trans-
plant lymphoproliferative disorders (PTLD) in immuno-
compromised patients. The successful treatment of EBV-
positive PTLD by the infusion of EBV-specific T-cell lines
has provided an important proof of principle for immu-
notherapy of EBV-associated tumors and for cancer
immunotherapy in general. EBV-specific T-cell preparations
for clinical application are generated by repeated stimu-
lation with autologous LCL in vitro. These lines contain
CD4+ and CD8+ components but the specificity of the
infused CD4+ T cells is still poorly defined. Using a mouse
model of PTLD, we assessed the antitumoral potential of
single virus-specific CD4+ T-cell clones. While T cells
specific for a virion antigen of the virus prolonged mouse
survival, other virus-specific clones had no effect or,
unexpectedly, even promoted tumor growth. Moreover,
the principal antitumoral effectors in LCL-stimulated T-cell
preparations were CD4+ T cells specific for non-virus
antigens. The definition of virion- and potentially autoan-
tigen-specific CD4+ T cells as key effectors against PTLD
may contribute to the design of generic and standardized
protocols for the generation of T-cell lines with improved
clinical efficacy. In addition, the observed tumor-promot-
ing propensity of some CD4+ T cells may have implications
for adoptive T-cell therapy in general.
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aim, different latent and lytic cycle antigen-specific CD4+ T-cell
clones, that recognize and growth-inhibit unmanipulated LCL to
various degrees in vitro [19,30], were injected together with
autologous LCL or PBMC and tumor latency analyzed.
As shown for the EBNA1- and EBNA3B-specific T-cell clones
1C3 and B9 [30], T cells that failed to recognize unmanipulated
LCL in vitro had no effect on mouse survival (Figure 3A). A possible
correlation of in vitro and in vivo effector functions was also
suggested by a slight, but statistically not yet significant prolon-
gation of mouse survival by the EBNA3C-specific T-cell clone
3H10, which moderately recognized LCL in vitro. Consistent with
these findings, tumor development was significantly delayed when
the BLLF1-specific T-cell clone 1D6 was transferred, which
recognized and growth-inhibited LCL very efficiently in vitro [19]
(Figure 3A). BLLF1-1D6-treated mice showed a median survival
benefit of 9.5 days, which is similar to mice that had received
tenfold less LCL (16106) without T cells (Figure 1C). Moreover,
similar results were obtained with this clone in the PBMC-SCID
mouse model, but these experiments have not yet reached
statistical significance due to the limited availability of large
numbers of PBMC from individual donors (data not shown).
These results indicated that single CD4+ T-cell specificities can
significantly prolong mouse survival and that tumor-protection
might correlate with target cell recognition and growth-inhibition
in vitro. This notion was further supported by experiments in
which 16107 CFSE-labeled BLLF1-specific or, as a control,
Figure 1. Induction of human PTLD-like tumors in immunodeficient mice. (A) Intraperitoneal injection of SCID mice with 16107 LCL of four
different donors led to tumor development with an incidence of 75 – 100% and a latency of 20 and 46 days (group sizes: LCL FL and LCL MF n = 4; LCL
GB n = 11; LCL JM n = 20; days p.i.: days post injection). (B) Injection of 16107 LCL, 16107 LCL Z(-), or 56107 PBMC from the same donor led to tumor
development in all animals but with different latency (group sizes: LCL JM n = 20; PBMC JM n = 6; LCL Z(-) JM n = 6). All survival curves and donor
dependent incidences and latencies were reproduced in several independent experiments. (C) Different numbers of LCL from the same donor were
injected in mice and the survival determined. Results are depicted in a Kaplan-Meier curve (group sizes: 16107 n = 20; 56106 n = 4; 16106 n = 6;
median survival 28, 30, and 38 days). (D) Developing tumors were confirmed as PTLD-like lymphomas. Formalin-fixed, paraffin-embedded tumor
slides (3–8 mm) were stained with H&E (first row) and with antibodies against the human B cell marker CD20 (second row), as well as antibodies
against the EBV latent proteins EBNA1 (third row) and EBNA2 (fourth row), whose co-expression is characteristic of PTLD.
doi:10.1371/journal.ppat.1004068.g001
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EBNA1-specific cells were i.p. injected into animals that had
received 16107 autologous LCL 25 days before and started
forming tumors. Both groups of mice were sacrificed 24, 48, or 72
hours after T-cell injection and the tumors analyzed by FACS
(Figure 3B) and immunohistochemistry (Figure 3C) for T-cell
infiltration. BLLF1- but not EBNA1-specific T cells accumulated
in tumors over time. Concomitantly, a reduction in the pro-
portion of human CD20+ cells was observed (Figure 3B). Some
BLLF1-specific T cells were even detected in direct contact with
BLLF1-positive cells (Figure 3C), lending further support to a
potential correlation of T-cell effector functions in vitro and in vivo.
However, infusion of the EBNA1-specific clone 3E10, that
failed to recognize unmanipulated LCL in vitro [30], and the
BNRF1-specific T-cell clone 1H7 (group size n = 10 and n = 4),
that efficiently recognized and growth-inhibited LCL in vitro [20],
accelerated tumor development (Figure 3D). When compared to
Figure 2. Analysis of the tumor-protective efficacy of CD4+ and CD8+ T cells in vivo. (A) Mouse survival after adoptive transfer of
autologous LCL-stimulated T cells. Mice were i.p. injected with 16107 LCL followed by a separate injection of an equal number of the indicated T cells
on the opposite side of the body. CD4+ and CD8+ T-cell populations prolonged mouse survival to a similar extent (LCL n = 20, LCL + T-cell line n = 6;
LCL + CD4+ T-cell line n = 4; LCL + CD8+ T-cell line n = 7). (B) Tumor-protective potential of different CD4/CD8 T-cell combinations. Separated CD4+
and CD8+ T-cell populations were recombined at different ratios and tested as described in (A). No significant increase in efficacy was observed
(group sizes: n = 4; p = 0.4457). Representative results from one out of three different donors are shown.
doi:10.1371/journal.ppat.1004068.g002
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Figure 3. EBV-specific CD4+ T cells differ in their tumor-protective potential. (A) Survival of mice after adoptive transfer of different EBV-
specific CD4+ T-cell clones. 16107 LCL and 16107 T cells were consecutively i.p. injected and mouse survival analyzed. As exemplified by the EBNA1-
specific T-cell clone 1C3 and the EBNA3B-specific clone B9, injection of latent antigen-specific T cells had no effect on mouse survival, except for
EBNA3C-specific CD4+ T cells that showed a trend towards delaying tumor growth (group sizes: EBNA1-1C3: LCL n = 20, LCL + T cells n = 11; EBNA3B-
B9: LCL n = 20, LCL + T cells n = 7; EBNA3C-3H10: LCL n = 11, LCL + T cells n = 4). Adoptive transfer of the BLLF1-specific CD4+ T-cell clone 1D6
prolonged mouse survival (group sizes: LCL n = 10; LCL + T cells n = 10; summarized results of 2 independently performed experiments). (B) CFSE-
labeled BLLF1- and EBNA1-specific T cells were i.p. injected into mice that had received autologous LCL 25 days before. Single cell suspensions of
tumors were analyzed 24, 48, or 72 hours post injection by FACS for the presence of CFSE-labeled T cells as well as human CD20-expressing tumor
cells. BLLF1- but not EBNA1-specific T cells infiltrated tumors and led to a decrease in the percentage of CD20+ cells. (C) Immunostaining of tumor
sections from mice described in (B). Cryo-embedded tumor sections were double-stained with FITC- and BLLF1-specific antibodies to detect tumor
infiltrated CFSE-labeled T cells (brown) and BLLF1-expressing tumor cells (blue). BLLF1-specific T cells infiltrated tumors and were found in proximity
to antigen expressing cells while no EBNA1-specific T cells were found to infiltrate the tumors. Two immunostainings of two separate tumor sections
T-Cell Therapy of EBV-Associated PTLD
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the tumor-protective clone BLLF1-1D6, these T cells responded to
their cognate antigen with similar affinity, secreted similar
amounts and patterns of cytokines, and displayed similar cytolytic
activity (Figure S1 in Text S1). These findings suggested that
besides target cell recognition and lytic activity, still unknown
functional differences among virus-specific CD4+ T cells may
impact on antitumoral efficacy.
Enriching virion antigen-specific CD4+ cells in T-cell
preparations confers no additional survival benefit in vivo
This tumor-promoting effect of some CD4+ T cells notwith-
standing, the above described experiments suggested that tumor-
protection in vivo correlates with T-cell recognition of target cells in
vitro. Since virion antigen-specific CD4+ T cells efficiently
recognize LCL in vitro, these results implicated CD4+ T cells
specific for structural antigens of the virus as particularly tumor-
protective. As demonstrated previously, the frequency of such T-
cell specificities is usually low in early passage T-cell lines, but
increases with further rounds of stimulation in vitro [20].
Accordingly, later passage LCL-stimulated T-cell lines might
exhibit a higher tumor-protective potential. As expected, T cells
from the same donor stimulated four or ten times in vitro both
recognized autologous LCL in vitro, but responses against virus-
pulsed LCL were more pronounced after ten rounds of
stimulation. These results indicated that the proportion of T cells
with virion antigen specificity had increased (Figure 4A and Figure
S2 in Text S1). When tested in vivo, both T-cell lines prolonged
median survival of LCL-injected animals to a similar extent; 50
days in the case of p4 (n = 13) and 46 days in the case of p10
(n = 13). Thus, despite an increased response against virus-pulsed
target cells, later passage T-cell lines were not more efficacious in
vivo (Figure 4B). In fact, the tumor-protective potential of these
LCL-stimulated T-cell lines seemed to decline with the number of
passages, either because extended in vitro culture impaired their
antitumoral activity in vivo, as demonstrated for CD8+ T cells [31],
and/or relevant specificities were lost.
The tumor-protective effect of LCL-stimulated T-cell lines
is mostly mediated by non-virion antigen-specific T cells
To investigate the antigen-specificity of protective T-cell lines in
more detail, we generated T-cell lines by repeated stimulation with
three different stimulator cells, (i) LCL cultured in media
containing FCS (LCL-FCS), (ii) LCL cultured in media containing
FCS and acyclovir (LCL-FCS-ACV), and (iii) LCL cultured in
media containing human serum (LCL-HS) instead of FCS. ACV
inhibits EBV late lytic gene expression and is used for safety
reasons in clinical T-cell stimulation protocols to prevent virus
production [32]. As verified in T-cell recognition assays, T-cell
lines stimulated with LCL-FCS-ACV were devoid of virion
antigen-specific T cells (Figure S3 in Text S1). LCL-HS were
used as stimulators to investigate whether recognition of FCS-
derived antigens presented on injected LCL by FCS-specific T
cells contributed to tumor protection [13].
Irrespective of the stimulator cells used, all three T-cell lines
recognized autologous LCL in vitro, but failed to respond to
autologous PBMC pulsed with recombinant EBV latent proteins
(Figure 5A). Efficient processing and presentation of peptides
derived from these recombinant proteins was confirmed using
latent antigen-specific CD4+ T-cell clones (Figure S4A in Text
S1). LCL-FCS and LCL-HS-stimulated T cells potentially
recognized EBV lytic cycle antigens and/or autoantigens, whereas
LCL-FCS-ACV-stimulated T cells might have been directed
against cellular antigens and possibly immediate early and early
lytic cycle antigens.
Surprisingly, in vivo all three T-cell lines significantly prolonged
median mouse survival to approximately 50 days (group sizes
n = 9-12) (Figure 5B). Thus, LCL-stimulated T-cell preparations
that lacked virion antigen-specific T cells were not compromised in
their antitumoral efficacy, indicating that tumor-protection was
mediated by T cells specific for non-virion antigens.
To further substantiate this notion, 8 mice were co-injected with
tumor-inducing cells that are unable to express lytic cycle antigens
(LCL Z(-)) and T cells stimulated with LCL-HS as effectors.
Although lytic cycle antigen-specific T cells, including virion
are shown in each case. (D) Injection of the EBNA1-specific T-cell clone 3E10 and the BNRF1-specific T-cell clone 1H7 led to faster tumor development
and shortened mouse survival (group sizes: EBNA1-3E10: LCL n = 20, LCL + T cells n = 10; BNRF1-1H7: LCL n = 20, LCL + T cells n = 4).
doi:10.1371/journal.ppat.1004068.g003
Figure 4. Later passage T-cell preparations show increased
virion antigen specificity but are less tumor-protective. (A)
Reactivity of the T-cell lines against virion antigens. With increasing
numbers of stimulation, the T-cell lines progressively responded against
virion antigens transferred by viral particles. T-cell specificity was tested
by cytokine secretion upon stimulation with autologous LCL Z(-). The
target cells were either left untreated or loaded with virus particles for
presentation of structural antigens (mainly late lytic antigens). (B)
Tumor protection by early and late passage T-cell lines. 16107 LCL and
16107 T cells stimulated with autologous LCL four (p4) or ten (p10)
times in vitro were simultaneously injected into SCID mice (group sizes:
LCL n = 20; LCL + T cells p4 n = 13; LCL + T cells p10 n = 13; depicted
results are combined from two independently performed experiments).
Later passage T-cell lines prolonged mouse survival less efficiently.
doi:10.1371/journal.ppat.1004068.g004
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antigen-specific T cells, were a priori ineffective in this experimental
setting, mouse survival was significantly prolonged with three out
of eight animals never developing any tumors (Figure 5C). No
human IgG was detected in the serum of these mice (data not
shown). Mice in this experiments survived on average for 86 days,
compared to 32 days without T cells (n = 7) (Figure 5C). Although
this remarkable protective efficacy might have been partly due to
the slightly less aggressive nature of LCL Z(-) as compared to LCL-
induced tumors (Figure 1B and [33-35]), these results clearly
demonstrated a considerable therapeutic potential of LCL-
stimulated T-cell lines independent of EBV latent or lytic cycle
antigen recognition.
CD4+ T cells specific for potential autoantigens prolong
mouse survival
To more directly evaluate the antitumoral efficacy of non-viral
antigen-specific T cells in vivo, T-cell lines were generated by
stimulation with LCL Z(-) or miniLCL, thereby precluding the
expansion of T cells that recognize EBV lytic cycle antigens.
Following more than 30 rounds of stimulation, these T cells
usually expressed one or few Vb chains, suggesting that these lines
were directed against one or few antigens (data not shown).
The miniLCL-stimulated T-cell line JM-W3 recognized
autologous LCL and LCL Z(-), as well as the HLA-matched
EBV-negative Burkitt’s lymphoma cell line BL30. Recognition was
not due to alloreactivity, because these T cells failed to recognize
the EBV-positive convertants (BL30-B95.8 and BL30-P3HR1).
Thus, this T-cell line recognized a differentially expressed cellular
antigen(s), but not viral antigens (Figure 6A and Figure S4C-D in
Text S1). In the case of the miniLCL-stimulated T-cell line GB-
W3, reactivity against EBV latent antigens was excluded by
assessing recognition of the HLA-matched, EBV-negative Hodg-
kin’s lymphoma cell line L428 that had been pulsed with single
recombinant EBV latent antigens (Figure 6A and Figure S4B in
Text S1). Co-injection of 16107 JM-W3 or GB-W3 T cells
together with 16107 autologous LCL Z(-) or miniLCL into
SCID mice prolonged median mouse survival from 30 to 36 days
in the case of JM-W3 T cells (group sizes LCL Z(-) n = 6; LCL Z(-)
+ T cells n = 4), and from 24 to 29 days in the case of GB-W3
(group sizes miniLCL n = 4; miniLCL + T cells n = 10),
demonstrating that autoantigen-specific T cells were tumor-
protective in this preclinical PTLD model (Figure 6B and Table
S1 in Text S1).
Similar to virus-specific effectors, these putative autoreactive T
cells displayed a differentiated effector/effector-memory Th1
phenotype [36,37] (CD62L2, CCR72, CD272, CD28+,
CXCR3+) (Figure 6C), that was confirmed by the expression of
the cytotoxins granzyme A and B in these T cells (Figure 6D).
Figure 5. Mouse survival is mediated by non-virus-specific T cells. T-cell lines were generated by four rounds of stimulation in vitro with LCL
cultivated in media containing human serum (HS), fetal calf serum (FCS), or fetal calf serum plus acyclovir (FCS-ACV) to prevent the expression and
presentation of virion antigens. (A) Specificity analysis of the generated T-cell lines. Autologous PBMC were pulsed with recombinant EBV latent
proteins [20] for 24 h and then probed with the T cells. Whereas all T-cell lines recognized LCL, none specifically responded against PBMC pulsed with
any of the latent proteins of EBV. (B) Following i.p. injection with autologous LCL as tumor inducing cells, all three T-cell lines prolonged mouse
survival significantly (*** p,0.0001). Group sizes: LCL n = 20; LCL + T-cell line HS n = 9; LCL + T-cell line FCS n = 12; LCL + T-cell line FCS-ACV n = 10
(summarized results of two independent experiments). (C) Injection of T-cell line HS together with LCL Z(-) significantly prolonged mouse survival,
demonstrating that virion antigen-specific T cells are not required for the tumor protective effect. Group sizes: LCL Z(-) n = 7; LCL Z(-) + T-cell line HS
n = 8 (*** p,0.0001).
doi:10.1371/journal.ppat.1004068.g005
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Discussion
The identification of low endogenous CD4+ T-cell numbers as
important risk factor for the development of EBV-associated
diseases in immunosuppressed patients [38], and of better clinical
responses in patients with PTLD receiving EBV-specific T-cell
lines that contained higher proportions of CD4+ T cells [10], have
implied an important role for CD4+ T cells in the control of EBV-
driven lymphoproliferation. Thus, elucidating the role of CD4+ T
cells in tumor defense may facilitate to generate T-cell prepara-
tions with enhanced clinical efficacy and to reduce the logistic
complexity of this form of immunotherapy that still precludes its
application outside specialized academic centers [3]. The EBV-
specific CD4+ T-cell response, albeit one to two orders lower in
magnitude, appears to target a much broader set of viral antigens
than the corresponding CD8+ T-cell response [6,14,20]. To
investigate whether these numerous CD4+ T-cell specificities are
functional redundant or fulfill complementary roles in tumor
defense, we assessed their tumor-protective potential in a
preclinical PTLD model.
In contrast to earlier [39], but in accordance with recently
published data [40], CD4+ T cells in our LCL-stimulated
preparations delayed tumor growth as effectively as the CD8+
components. Contrary to the above mentioned clinical experience,
however, antitumoral efficacy was not affected by the CD4/CD8
ratio of the injected T-cell preparations. This functional redun-
dancy implied that both components recognized PTLD-like
tumors with similar efficiency. In patients, CD4+ T cells probably
also exert indirect ‘‘helper’’ functions that remained undetected in
this xenogenic model, where human T cells fail to persist long-
term and complex immune networks are unlikely to form.
To assess functional differences among virus-specific CD4+ T
cells we injected T-cell clones with defined specificities together
with autologous LCL or PBMC from EBV-seropositive donors
into SCID mice. Unexpectedly, the T-cell clones had divergent
effects on mouse survival, ranging from tumor-protective in the
case of BLLF1-specific T cells, to ineffective in the case of most
latent antigen-specific T cells, to tumor growth-promoting in the
case of EBNA1-3E10 and BNRF1-1H7. The correlation of tumor-
protective but not tumor-promoting propensity of T cells in vivo
with target cell recognition and inhibition of proliferation in vitro
suggested that still unknown phenotypic differences may exist
between these populations. Neither the pattern nor the amount of
secreted cytokines, including paracrine growth factors like IL-6
that are known to shorten tumor latency in SCID mice [34,35,41],
differed consistently among tumor-promoting and tumor-protec-
tive T cells (Figure S1 in Text S1, and data not shown). How
certain CD4+ T cells promote tumor growth is still unknown, but
given the potential clinical implications, warrants further investi-
gation. This dichotomous function of CD4+ T cells may also
provide an explanation for the contrasting effects of LCL-
stimulated CD4+ T-cell lines on tumor growth in different studies
[39,40], and for the baffling observation that tumor development
in SCID mice injected with primary B cells from EBV-positive
donors depends on the presence of T cells [33].
Unexpectedly, EBNA1-specific CD4+ T cells had no or a tumor
growth-promoting effect in vivo. This was surprising because
EBNA1 peptide-selected T-cell preparations were successfully used
in the clinic to treat PTLD [42]. The reasons for these discrepant
results are currently not known. The clinically used T-cell
preparations, however, contained CD4+ and CD8+ T-cell
components and only about 60% of the adoptively transferred T
cells were EBNA1-specific. Therefore, it cannot be excluded that
tumor regression was mediated by EBNA1-specific CD8+ T cells
and/or T cells with undefined specificities. An important role of
CD8+ T cells in the control of PTLD has been implicated by
clinical studies using peptide or MHC class I pentamer-selected T-
cell preparations [7,8]. The infused T cells were predominantly
CD8+ and were directed against different viral antigens.
Collectively, these studies point towards a redundant function of
different latent or lytic antigen-specific T cells in the control of
PTLD in stem cell transplant recipients. However, in solid organ
transplant recipients, response rates are generally lower (around
50%) and positively correlate with the CD4+ T-cell content of the
infused T-cell preparations [10], suggesting that in these patients,
CD4+ and CD8+ T cells do not have completely redundant
antitumoral functions. Whether virus-specific CD4+ T cells,
including those directed against EBNA1 as well as other viral
antigens, that had no effect on tumor growth in the SCID mouse
model, are of therapeutic importance in this cohort, e.g. by
providing help to endogenous immune cells, remains to be
determined.
The efficient recognition of LCL by virion antigen-specific T
cells [19] and the correlation of target cell recognition and
prolongation of mouse survival implied that increasing virion
antigen-specific CD4+ T cells in T-cell preparations might
increase their tumor-protective potential. This notion was
supported by immunohistochemical analyses of tumor sections
which revealed that approximately 1–3% of the tumor cells
expressed BZLF1 (data not shown). A similar percentage of
BZLF1-positive cells was detected in the corresponding LCL
cultures, suggesting that spontaneous induction of the lytic cycle
and expression of lytic cycle antigens was not altered in vivo.
However, LCL-stimulated T-cell lines were not more tumor-
protective at later than at earlier passage. This was either because
(i) functionality of the T cells in vivo declined with longer in vitro
culture [31], or (ii) tumor-protective T-cell specificities were lost
and only partially compensated for by the increase in virion
antigen-specific T cells, and/or (iii) tumor-promoting T cells were
enriched. To further analyze antigen-specificity and antitumoral
efficacy of early passage T-cell preparations, we compared the
tumor-protective potential of T-cell lines stimulated with LCL that
had been cultured under different conditions, including those used
in clinical protocols [43]. These experiments revealed that
potentially autoantigen-specific, but not FCS-reactive or virus-
specific T cells, were the principal effectors against PTLD in early
Figure 6. LCL Z(-)- as well as miniLCL-stimulated T-cell lines recognize autoantigens and prolong mouse survival. (A) Recognition of
autoantigens by LCL Z(-) or miniLCL-stimulated T cells. Specificity analysis of the T-cell line JM-W3 was performed using autologous LCL and LCL Z(-)
as well as HLA-matched EBV-negative and EBV-positive BL30 cell lines. T-cell recognition of the EBV-negative BL30 cell line, but barely of BL30 cells
that had been infected with the B95.8 or the P3HR1 EBV strains, demonstrated that these T cells recognized a non-viral antigen(s). Recognition of viral
antigens by the GB-W3 T cells was excluded by probing the cells with the HLA-matched, EBV-negative Hodgkin lymphoma cell line L428 pulsed with
recombinant latent proteins of EBV. (B) Analysis of the tumor-protective potential of these autoreactive T-cell lines in vivo. 16107 LCL Z(-) or miniLCL
were i.p. injected in combination with 16107 autologous T cells and tumor development assessed (LCL Z(-) n = 6; LCL Z(-) + T cells JM-W3 n = 4;
miniLCL n = 4; miniLCL + T cells GB-W3 n = 10; * p,0.05; *** p,0.001) (C) Phenotypic characterization of the autoreactive T cells GB-W3 by FACS.
Autoreactive T cells displayed a CD3+CD4+ effector T-cell phenotype (CD62L-CCR7-) of differentiated T cells (CD27-CD28+CXCR3+CCR4-CCR6+/-), and
produced granzyme A (black line) and B (grey line) (D).
doi:10.1371/journal.ppat.1004068.g006
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passage LCL-stimulated CD4+ T-cell lines. These T cells
prolonged mouse survival as effectively as a virion antigen-specific
T-cell clone, implicating these two specificities as critical CD4+
effectors against PTLD in this preclinical model. However, one
has to keep in mind that only a limited number of T-cell clones
directed against a subset of all viral antigens was included in this
analysis. Thus, additional T-cell specificities with protective
efficacy may exist.
That autoantigen-specific CD4+ T cells are a major component
of early passage LCL-stimulated T-cell preparations, has already
been demonstrated in earlier studies [20]. Furthermore, when the
expansion of lytic cycle antigen-specific T cells was prevented by
using LCL Z(-) cells as stimulators, the resulting CD4+ T-cell lines
targeted cellular but not viral antigens [21].
Although the antigens recognized by these T cells have yet to be
defined molecularly, their expression appears to be restricted to
transformed B-cell lines and was not detected in primary
hematopoietic cells (Figure S4 in Text S1). In accordance with
this, Long et al recently isolated CD4+ T-cell clones from LCL-
stimulated lines that recognize cellular antigens expressed in EBV-
transformed, but not in mitogen-activated B lymphoblasts [21].
These findings may provide an explanation for the proven clinical
safety of LCL-stimulated T-cell preparations [5,6,44]. In addition,
these findings raise the intriguing possibility that EBV-positive
lymphomas that fail to express immunodominant antigens of EBV,
e.g. Hodgkin’s and Burkitt’s lymphoma, and even EBV-negative B
cell malignancies, might respond to LCL-stimulated T-cell
preparations.
Circumstantial evidence for a protective role of autoreactive
CD4+ T cells has already been obtained in preclinical lymphoma
models and lymphoma patients: CD4+ T cells that recognize non-
viral antigens can prevent B cell lymphomas in mice transgenic for
the EBV latent membrane protein LMP1 [45], and five of six
patients with Hodgkin’s-like and Burkitt’s-like post-transplant
lymphoproliferative disease responded to treatment with alloge-
neic T-cell preparations, although in some cases the tumor cells
did not express the viral antigens recognized by the infused T cells
[11]. Moreover, complete remissions were achieved in several
patients with LMP2A-positive Hodgkin’s lymphoma by the
adoptive transfer of autologous LCL-stimulated T-cell lines. Since
the infused T cells contained only low amounts of LMP2A-specific
CD8+ T cells and their frequencies failed to correlate with clinical
responses [5,46], additional and still unknown specificities might
have contributed to tumor rejection.
Taken together, these results implicate virion and non-viral
antigens as important targets of the CD4+ T-cell response against
PTLD, and LCL-stimulated T-cell lines, although increasingly
replaced by antigen-specific preparations [8,9,47], as more potent
than previously recognized. Defining the antigens recognized by
these non-viral antigen-specific CD4+ T cells and incorporating
such specificities in clinically used T-cell preparations may not
only increase their antitumoral activity against PTLD, but possibly
also against EBV-negative B cell malignancies.
Materials and Methods
Ethics statement
All animal experiments were performed in strict accordance
with German animal protection law (TierSchG) and approved by
the responsible state office Regierung von Oberbayern (ROB)
under protocol number 55.2-1-54-2531-131-07. The mice were
housed and handled in accordance with good animal practice and
all efforts were made to minimize suffering as defined by
Federation of European Laboratory Animal Science Associations
(FELASA) and the national animal welfare body Gesellschaft für
Versuchstierkunde - Society for Laboratory Animal Science
(GV-SOLAS).
Generation and cultivation of LCL
LCL were established by infection of primary B cells with wild-
type (wt)-EBV produced by the B95.8 marmoset cell line.
MiniLCL and LCL Z(-) were generated by infection of B cells
with the genetically engineered virus mutants miniEBV [48] and
DBZLF1-EBV [49] that are incapable of lytic replication, as
previously described [19]. B cells were obtained from peripheral
blood mononuclear cells (PBMC) of healthy adult volunteers after
informed consent. LCL were cultured as described [20]. In some
experiments, FCS was replaced by pooled human serum (HS) to
avoid the expansion of FCS-reactive T cells. Where indicated,
LCL treated with 200 mM acyclovir (ACV) (Hexal) for at least two
weeks were used as T-cell targets.
Generation and cultivation of T cells
PBMC were repeatedly stimulated with autologous, irradiated
(80 Gy) LCL, miniLCL, or LCL Z(-) as antigen presenting cells
(APC) as described [20]. Where indicated, T-cell lines were
separated into CD4+ and CD8+ fractions by using aCD4+ and
aCD8+ MicroBeads, LS-MACS columns and MidiMACS sepa-
rator as recommended by the manufacturer (Miltenyi Biotec).
Purity of the cells was confirmed by FACS analysis using CD3,
CD4, and CD8-specific antibodies (Becton Dickinson). Generation
and cultivation of CD4+ T-cell clones has been described
previously [19,30]. Clonality of the T cells was assessed by PCR
using Vb chain-specific primers as described, and T-cell epitopes
as well as the restricting HLA-molecules were identified using
published methods [13,50]. To exclude that prolonged culture
caused loss of specificity of the T cells and, consequently, that their
anti-tumor effect in vivo would not reflect their initial anti-tumor
activity in vitro, antigen-specificity of all clones was verified prior to
injection (data not shown and Fig S4 in Text S1).
The T-cell lines were generated by stimulation with autologous
LCL or miniLCL. The T-cell lines were 100% CD3+ with varying
proportions of CD4+ and CD8+ components. No NK or B cells
were detected by FACS. Target cell recognition and lytic activity
of all T cells was tested prior to injection (data not shown).
Cytokine secretion by the T cells was measured by ELISA (R&D
Systems). Plotted data represent the mean plus standard deviation
(SD) of triplicates. Dendritic cells and PHA blasts were generated
as described [51]. Cytolytic activity was measured after 3 h of co-
culture of T cells with labeled target cells by quantitating calcein
AM (Invitrogen) released into the culture supernatant. Virus
concentrate was prepared by ultracentrifugation of B95.8 cell
culture supernatant. Functionality was tested using BLLF1-specific
T cells (Figure S3 in Text S1) and viral copy numbers determined
by qPCR as described [13].
In vivo studies
To assess the antitumoral potential of T cells in vivo, 16107 LCL
(LCL-SCID mouse model) or 56107 PBMC (PBMC-SCID mouse
model) from EBV-positive donors were injected intraperitoneally
(i.p.) into 6 to 14-weeks-old C.B.17-SCID mice (Taconic). 16107
T cells in PBS, or PBS only, were i.p. injected separately on the
same day before down-regulation of HLA class-II on injected LCL
occurs [40,52]. All cells injected in mice were tested negative for
mycoplasma using a commercial detection kit (Lonza). For T-cell
tracking experiments, LCL were injected on day 0 and T cells on
day 25. Experimental groups consisting of 4–6 mice were
evaluated for tumor growth and survival. Mice were sacrificed
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when they had ruffled hair, showed food refusal, bulky abdomen
or palpable tumors. To verify the presence of human B cells in
these mice, human IgG (huIgG)-ELISA was performed. 96-well
plates were coated with a-human IgG mAb (2.5 mg/ml; Abcam) in
PBS overnight and then incubated with mouse serum at different
dilutions in RPMI-1640 for 1 h. Subsequently, the biotin-labeled
detection antibody a-huIgG (Dianova) was added for 1 h followed
by horseradish-peroxidase (HRP)-coupled streptavidin for 20 min.
HuIgG was visualized by adding TMB-substrate.
Where indicated, T cells were labeled with CFSE according to
the guidelines of the manufacturer (Invitrogen). For the FACS-
analysis of tumor infiltration by CFSE-labeled T cells, single cell
suspensions of tumors were prepared by mechanical disruption
and lysis of erythrocytes.
FACS
For FACS analysis, fluorochrome-conjugated monoclonal
antibodies against human CD3, CD4, CD8, CD25, CD28,
CD57, CD62L, CXCR3, CCR4, CCR6, CCR7, CTLA-4,
MHC II, PD-1 (Becton Dickinson), CD20, CD27 and MHC I
(ImmunoTools) were used. TIM-3 antibody (kindly provided by
Dr. Kuchroo, Boston) was visualized using a fluorochrome-
conjugated secondary antibody (Jackson ImmunoResearch labo-
ratories). Granzyme A and B stainings were performed on a-CD3-
activated T cells. Dead cells were excluded with 7-AAD (Becton
Dickinson), cells fixed with paraformaldehyde, permeabilized with
saponine and stained for granzyme A and B. FoxP3 staining was
performed following the manufacturers protocol using the Fix/
Perm FoxP3 buffer set (BioLegend). CD4+ cells were stained prior
to fixation, CD25+ cells were stained simultaneously with FoxP3.
CD107a antibody (BioLegend) was added during T-cell stimula-
tion and surface expression analyzed after 4 h. Flow cytometric
analysis was performed in a FACSCalibur flow cytometer and
data analyzed with the CellQuest software (Becton Dickinson).
Immunohistochemistry
Immunohistochemical analyses were performed on cryo-
embedded or formalin-fixed, paraffin-embedded (FFPE) tumor
samples. FFPE-sections of all tumors were stained with
hematoxylin and eosin (H&E), or with antibodies against human
CD20, EBNA1, EBNA2, BZLF1, BLLF1, and FITC (from
Argene, Dako, or kindly provided by Dr. E. Kremmer,
Helmholtz Zentrum München). For H&E staining, FFPE
sections were stained with mayers hematoxylin solution and
eosin Y (both Roth). Single stain immunohistochemistry was
performed on FFPE sections using the Vectastain ABC
Detection System for horseradish peroxidase according to the
manufacturers protocol (Vector Laboratories). Cryo-embedded
sections were used for double-stainings with antibodies against
FITC, to detect CFSE-labeled T cells, and BLLF1, to detect
lytically infected tumor cells. In addition to the horseradish
peroxidase detection system, the Vectastain ABC Detection
System for alkaline phosphatase in combination with the
alkaline phosphate substrate kit III (both from Vectastain) was
used.
Statistical analysis
Mouse survival was analyzed using Kaplan-Meier curves.
Significances of the in vivo-experiments were calculated by using
the log-rank or the Kruskal-Wallis test. p-values of 0.05 or less
were considered significant. The statistical analyses were carried
out with the GraphPad Prism 5 program.
Supporting Information
Text S1 Supporting information. This file contains Figures S1-
S5 and Table S1.
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